Surgery (RMH) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 5 of 5
  • Item
    Thumbnail Image
    Guesstimates are not good enough for determining what is happening in routine care
    Heong, V ; Ananda, S ; Tie, J ; Gibbs, P (NATURE PUBLISHING GROUP, 2010-12-07)
  • Item
    Thumbnail Image
    Cancer classification using the Immunoscore: a worldwide task force
    Galon, J ; Pages, F ; Marincola, FM ; Angell, HK ; Thurin, M ; Lugli, A ; Zlobec, I ; Berger, A ; Bifulco, C ; Botti, G ; Tatangelo, F ; Britten, CM ; Kreiter, S ; Chouchane, L ; Delrio, P ; Arndt, H ; Asslaber, M ; Maio, M ; Masucci, GV ; Mihm, M ; Vidal-Vanaclocha, F ; Allison, JP ; Gnjatic, S ; Hakansson, L ; Huber, C ; Singh-Jasuja, H ; Ottensmeier, C ; Zwierzina, H ; Laghi, L ; Grizzi, F ; Ohashi, PS ; Shaw, PA ; Clarke, BA ; Wouters, BG ; Kawakami, Y ; Hazama, S ; Okuno, K ; Wang, E ; O'Donnell-Tormey, J ; Lagorce, C ; Pawelec, G ; Nishimura, MI ; Hawkins, R ; Lapointe, R ; Lundqvist, A ; Khleif, SN ; Ogino, S ; Gibbs, P ; Waring, P ; Sato, N ; Torigoe, T ; Itoh, K ; Patel, PS ; Shukla, SN ; Palmqvist, R ; Nagtegaal, ID ; Wang, Y ; D'Arrigo, C ; Kopetz, S ; Sinicrope, FA ; Trinchieri, G ; Gajewski, TF ; Ascierto, PA ; Fox, BA (BMC, 2012-10-03)
    Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the 'Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).
  • Item
    Thumbnail Image
    Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13
    Spain, SL ; Carvajal-Carmona, LG ; Howarth, KM ; Jones, AM ; Su, Z ; Cazier, J-B ; Williams, J ; Aaltonen, LA ; Pharoah, P ; Kerr, DJ ; Cheadle, J ; Li, L ; Casey, G ; Vodicka, P ; Sieber, O ; Lipton, L ; Gibbs, P ; Martin, NG ; Montgomery, GW ; Young, J ; Baird, PN ; Morreau, H ; van Wezel, T ; Ruiz-Ponte, C ; Fernandez-Rozadilla, C ; Carracedo, A ; Castells, A ; Castellvi-Bel, S ; Dunlop, M ; Houlston, RS ; Tomlinson, IPM (OXFORD UNIV PRESS, 2012-02-15)
    In genome-wide association studies (GWASs) of colorectal cancer, we have identified two genomic regions in which pairs of tagging-single nucleotide polymorphisms (tagSNPs) are associated with disease; these comprise chromosomes 1q41 (rs6691170, rs6687758) and 12q13.13 (rs7163702, rs11169552). We investigated these regions further, aiming to determine whether they contain more than one independent association signal and/or to identify the SNPs most strongly associated with disease. Genotyping of additional sample sets at the original tagSNPs showed that, for both regions, the two tagSNPs were unlikely to identify a single haplotype on which the functional variation lay. Conversely, one of the pair of SNPs did not fully capture the association signal in each region. We therefore undertook more detailed analyses, using imputation, logistic regression, genealogical analysis using the GENECLUSTER program and haplotype analysis. In the 1q41 region, the SNP rs11118883 emerged as a strong candidate based on all these analyses, sufficient to account for the signals at both rs6691170 and rs6687758. rs11118883 lies within a region with strong evidence of transcriptional regulatory activity and has been associated with expression of PDGFRB mRNA. For 12q13.13, a complex situation was found: SNP rs7972465 showed stronger association than either rs11169552 or rs7136702, and GENECLUSTER found no good evidence for a two-SNP model. However, logistic regression and haplotype analyses supported a two-SNP model, in which a signal at the SNP rs706793 was added to that at rs11169552. Post-GWAS fine-mapping studies are challenging, but the use of multiple tools can assist in identifying candidate functional variants in at least some cases.
  • Item
    Thumbnail Image
    Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer
    Tomlinson, IPM ; Carvajal-Carmona, LG ; Dobbins, SE ; Tenesa, A ; Jones, AM ; Howarth, K ; Palles, C ; Broderick, P ; Jaeger, EEM ; Farrington, S ; Lewis, A ; Prendergast, JGD ; Pittman, AM ; Theodoratou, E ; Olver, B ; Walker, M ; Penegar, S ; Barclay, E ; Whiffin, N ; Martin, L ; Ballereau, S ; Lloyd, A ; Gorman, M ; Lubbe, S ; Howie, B ; Marchini, J ; Ruiz-Ponte, C ; Fernandez-Rozadilla, C ; Castells, A ; Carracedo, A ; Castellvi-Bel, S ; Duggan, D ; Conti, D ; Cazier, J-B ; Campbell, H ; Sieber, O ; Lipton, L ; Gibbs, P ; Martin, NG ; Montgomery, GW ; Young, J ; Baird, PN ; Gallinger, S ; Newcomb, P ; Hopper, J ; Jenkins, MA ; Aaltonen, LA ; Kerr, DJ ; Cheadle, J ; Pharoah, P ; Casey, G ; Houlston, RS ; Dunlop, MG ; Gibson, G (PUBLIC LIBRARY SCIENCE, 2011-06)
    Genome-wide association studies (GWAS) have identified 14 tagging single nucleotide polymorphisms (tagSNPs) that are associated with the risk of colorectal cancer (CRC), and several of these tagSNPs are near bone morphogenetic protein (BMP) pathway loci. The penalty of multiple testing implicit in GWAS increases the attraction of complementary approaches for disease gene discovery, including candidate gene- or pathway-based analyses. The strongest candidate loci for additional predisposition SNPs are arguably those already known both to have functional relevance and to be involved in disease risk. To investigate this proposition, we searched for novel CRC susceptibility variants close to the BMP pathway genes GREM1 (15q13.3), BMP4 (14q22.2), and BMP2 (20p12.3) using sample sets totalling 24,910 CRC cases and 26,275 controls. We identified new, independent CRC predisposition SNPs close to BMP4 (rs1957636, P = 3.93×10(-10)) and BMP2 (rs4813802, P = 4.65×10(-11)). Near GREM1, we found using fine-mapping that the previously-identified association between tagSNP rs4779584 and CRC actually resulted from two independent signals represented by rs16969681 (P = 5.33×10(-8)) and rs11632715 (P = 2.30×10(-10)). As low-penetrance predisposition variants become harder to identify-owing to small effect sizes and/or low risk allele frequencies-approaches based on informed candidate gene selection may become increasingly attractive. Our data emphasise that genetic fine-mapping studies can deconvolute associations that have arisen owing to independent correlation of a tagSNP with more than one functional SNP, thus explaining some of the apparently missing heritability of common diseases.
  • Item
    Thumbnail Image
    A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy
    Lim, L ; Gibbs, P ; Yip, D ; Shapiro, JD ; Dowling, R ; Smith, D ; Little, A ; Bailey, W ; Liechtenstein, M (BMC, 2005-10-15)
    BACKGROUND: To prospectively evaluate the efficacy and safety of Selective Internal Radiation (SIR) spheres in patients with inoperable liver metastases from colorectal cancer who have failed 5FU based chemotherapy. METHODS: Patients were prospectively enrolled at three Australian centres. All patients had previously received 5-FU based chemotherapy for metastatic colorectal cancer. Patients were ECOG 0-2 and had liver dominant or liver only disease. Concurrent 5-FU was given at investigator discretion. RESULTS: Thirty patients were treated between January 2002 and March 2004. As of July 2004 the median follow-up is 18.3 months. Median patient age was 61.7 years (range 36-77). Twenty-nine patients are evaluable for toxicity and response. There were 10 partial responses (33%), with the median duration of response being 8.3 months (range 2-18) and median time to progression of 5.3 mths. Response rates were lower (21%) and progression free survival shorter (3.9 mths) in patients that had received all standard chemotherapy options (n = 14). No responses were seen in patients with a poor performance status (n = 3) or extrahepatic disease (n = 6). Overall treatment related toxicity was acceptable, however significant late toxicity included 4 cases of gastric ulceration. CONCLUSION: In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity. Further studies are required to better define the subsets of patients most likely to respond.